Delphine Courmier | Health Economics Director, Biosimilars
Amgen Inc

Delphine Courmier, Health Economics Director, Biosimilars, Amgen Inc

Dr Delphine Courmier is a Health Economics Director at Amgen with the responsibility of the biosimilar portfolio in the HTA Center of Excellence as well as Global Health Economics for the oncology biosimilars.

Delphine joins from Baxter where she was Global Market Access lead for 2 hospital products global Franchises. Prior to this role, she worked in Market Access and Health Economics both in consulting and industry in pharma (Novartis, Ipsen) and medical devices (J&J) since 2010. Her earlier career was in R&D in material design for various industries. Her last R&D project before switching to Market Access was to develop semiconductor-based sensors for airborne pathogens.

Delphine has an MBA from London Business School, a Ph.D. in Computational Chemistry from the University of Ottawa, Canada, an MSc. and BSc. in Chemistry from Université Pierre et Marie Curie Paris 6, France and a European Market Access University Diploma from Université Claude Bernard Lyon 1, France.

Appearances:



Biosimilars Day 1 - Tuesday 29th October 2018 @ 14:30

Oncology biosimilars: the vastly evolving HTA landscape

  • Biosimilar national HTA archetypes
  • Integrating Biosimilars in the therapeutic strategy:
  • Reimbursement in extrapolated indications, reimbursement of a biosimilar when the originator was not cost-effective, pharmacy substitution
  • Hospital-Based HTA for Biosimilars: How do providers and hospitals decide which biosimilar to list on their formulary?
last published: 17/Jul/18 15:35 GMT
last published: 17/Jul/18 15:35 GMT

back to speakers

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates